Methods and compositions for generating full-length cDNA having arbitrary nucleotide sequence at the 3'-end

• US 5,962,271 A
• Filed: 01/03/1996
• Issued: 10/05/1999
• Est. Priority Date: 01/03/1996
• Status: Expired due to Term

• Current Assignee: Clontech Laboratories Incorporated
• Original Assignee: Clontech Laboratories Incorporated
• Inventors: Diatchenko, Luda, Chenchik, Alex, Zhu, York, Siebert, Paul
• Primary Examiner(s): Horlick, Kenneth R.
• Application Number:
  US08/582,562
• Time in Patent Office: 1,371 Days
• Field of Search: 435/91.1, 536/23.1, 536/24.2, 536/25.3
• US Class Current: 435/91.1
• CPC Class Codes: C12N 15/1096 cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
• CPC Class Codes: C12Q 1/6855 Ligating adaptors

Abstract

Described are compositions and methods which allow for the efficient addition of a defined sequence at the 3'"'"'-end of a full-length cDNA in the course of first-strand cDNA synthesis from an mRNA template. A cDNA synthesis primer that is capable of annealing to mRNA is used to prime the first strand synthesis reaction. An oligonucleotide that is linked to the 5'"'"'-end of the mRNA serves as a short, extended template such that when the reverse transcriptase enzyme reaches the 5'"'"'-end of the mRNA, the enzyme switches templates and proceeds to transcribe through the end of the linked oligonucleotide. As a result, the single-stranded cDNA product which corresponds to the full-length mRNA, will have at the 3'"'"'-end a defined sequence which is complementary to the linked oligonucleotide. A conservative element in the oligonucleotide sequence responsible for this reaction can include 3 to 5 guanylic acid residues at the 3'"'"'-end of the oligonucleotide. The subject invention provides for the increased synthesis of full-length cDNA from mRNA templates. The full-length cDNA prepared according to the present invention can then be amplified using PCR or cloned using standard procedures.

Claims

1. A template switching oligonucleotide capable of selectively interacting with a 5'"'"' CAP structure of a full-length mRNA-cDNA intermediate generated by reverse transcription of mRNA, wherein when said template switching oligonucleotide interacts with said 5'"'"' CAP structure of said full-length mRNA-cDNA intermediate, said template switching oligonucleotide is capable of serving as a template for additional reverse transcription such that a sequence complementary to said template switching oligonucleotide is incorporated at a 3'"'"'-end of a cDNA.

2. The template switching oligonucleotide of claim 1, wherein said template switching oligonucleotide has a general formula:

5'"'"'-dN₁ -dN₂ - . . . dNm-rN1-rN₂ . . . rNn-3'"'"';

wherein dN represents a deoxyribonucleotide;

m represents an interger, rN represents a ribonucleotide at least one of which is GMP; and

n represents an interger.

3. The template switching oligonucleotide of claim 2, wherein m represents an interger of 10 to 50.

4. The template-switching oligonucleotide of claim 2, wherein n represents an interger of 3-7.

5. The template switching oligonucleotide of claim 2, wherein said deoxyribonucleotides are selected from the group consisting of dAMP, dGMP, dCMP, cTMP, modified nucleotides and non-natural nucleotides.

6. The template switching oligonucleotide of claim 2, wherein said ribonucleotides are selected from the group consisting of AMP, GMP, CMP, UMP, modified nucleotides, non-natural nucleotides, and terminator nucleotides.

7. The template switching oligonucleotide of claim 2, wherein said ribonucleotides include at least two GMP ribonucleotides.

8. The template switching oligonucleotide of claim 2, wherein said ribonucleotides include at least three GMP ribonucleotides.

9. The template switching oligonucleotide of claim 2, wherein said template switching oligonucleotide is selected from the group consisting of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 4 through SEQ ID NO. 7, SEQ ID NO. 9, SEQ ID NO. 13 and SEQ ID NO. 13 through SEQ ID NO. 66.

10. The template switching oligonucleotide of claim 2, wherein said template switching oligonucleotide comprises a guanylic acid residue at its 3'"'"' end, wherein a 3'"'"'-OH group of a ribose portion of said guanylic acid residue comprises a chemical group selected from the group consisting of amino, biotin, phosphate and glycerol.

11. The template switching oligonucleotide of claim 2, wherein said template switching oligonucleotide has a general formula:

5'"'"'-dN_18-30 -rG_3-5 -3'"'"'.

12. The template switching oligonucleotide of claim 2, wherein said deoxyribonucleotide portion of said oligonucleotide comprises at least one restriction site.

13. The template switching oligonucleotide of claim 2, wherein said template switching oligonucleotide comprises a protein portion which binds to a 5'"'"' CAP of a mRNA molecule.

14. The template switching oligonucleotide of claim 13, wherein said protein portion is selected from the group consisting of eucaryotic initiation factor 4E and anti-CAP structure antibodies.

15. A method for generating cDNA, comprising the steps of:

combining an RNA sample with a cDNA synthesis primer under conditions sufficient to allow annealing of said cDNA synthesis primer to mRNA in said RNA sample to produce a primer-mRNA complex;

incubating said primer-mRNA complex with enzyme, dNTPs and buffer under conditions which permit template-dependent extension of said primer to generate an mRNA-cDNA hybrid; and

contacting said mRNA-cDNA hybrid with the template switching oligonucleotide of claim 1 under conditions which permit template-dependent extension of said cDNA of said hybrid, such that a 3'"'"' end of said cDNA sequence of said hybrid comprises a sequence complementary to said template switching oligonucleotide.